Author's response to reviews

Title: MicroRNA-144 suppresses cholangiocarcinoma cell proliferation and invasion through targeting platelet activating factor acetylhydrolase isoform 1b

Authors:

- Rui Yang (YR1975@126.com)
- Yongjun Chen (chenyongjun45@126.com)
- Cong Tang (congtusys@yeah.net)
- Hongbo Li (lhb860312@gmail.com)
- Bing Wang (t0013008@aliyun.com)
- Qun Yan (yixianju@126.com)
- Junbo Hu (jbhu@tjh.tjmu.edu.cn)
- Shengquan Zou (sqzou05@aliyun.com)

Version: 4 Date: 10 September 2014

Author's response to reviews:

The BMC Cancer Editorial Team:

Thank you for your letter and for the editorial request's comments concerning our manuscript entitled “MicroRNA-144 suppresses cholangiocarcinoma cell proliferation and invasion through targeting platelet activating factor acetylhydrolase isoform 1b” (MS: 1910821527127704). Those comments are all valuable and very helpful for revising and improving our paper, as well as the important guiding significance to our researches. We have revised editorial request carefully and have made correction which we hope meet with approval.

Reviewer's report

Minor Essential Revisions
1. The authors use the word ? Infection? (for plasmids and for siRNA oligos) where ? transfection? should instead be used.

We are so sorry about our mistakes. We have already modified it in revised manuscript.

2. How did the overexpression of miR-144 and/or reduction of LIS1 expression resulted in suppression of Akt phosphorylation and MMP2 expression? How is it involved in suppression CCA cell proliferation, invasion and motility? (The answer given in their rebuttal is unsatisfactory !).

We are so sorry about our unclear expression. We have already modified it in revised manuscript and added some statements in the section of results.

3. Most important, the manuscript needs an extensive copyediting by native English speaking scientists (as also noted in the first round of review). In their rebuttal the Authors state that ?I have revised our language editing by Elsevier?.

I have revised our language editing by Elsevier again.
Sincerely yours,
Shengquan Zou, PhD, MD